Imprudent use of proton pump inhibitors in current practice

Authors

  • Manali Mangesh Mahajan Department of Pharmacology, Indira Gandhi Government Medical College & Hospital, Nagpur, Maharashtra, India
  • Sujata Dudhgaonkar Department of Pharmacology, Indira Gandhi Government Medical College & Hospital, Nagpur, Maharashtra, India
  • Swapnil Narayan Deshmukh Department of Pharmacology, Indira Gandhi Government Medical College & Hospital, Nagpur, Maharashtra, India

Keywords:

Gastroprotective agents, Acid peptic disease, Proton pump inhitors

Abstract

In a developing country like India, where over 500 branded formulations of PPI are available, probability of misuse and abuse increases exponentially. Although a safe and very effective class of pharmaceutical agent, PPIs should be used only when there is documented evidence of a GI disorder that cannot be treated with an H2-receptor antagonist, and where a PPI use is clinically justified. Increased clinician awareness on appropriate PPI prescription will lead to better patient outcome at lower cost.

References

Tripathi KD. Drugs for peptic ulcer and GERD. Essentials of Medical Pharmacology. 17th Edition. Chapter. 46. New Delhi: Jaypee; 2013: 647-60.

Van der Hulst RW, Rauws EA, Köycü B, Keller JJ, Bruno MJ, Tijssen JG, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology. 1997;113:1082-6.

Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383-91, 1391.e1.

Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359(16):1700-7.

Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120-8.

Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769-84.

Naunton M, Peterson G, Bleasel M. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333-8.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-26.

Gau JT, Heh V, Acharya U, Yang YX, Kao TC. Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf. 2009;18(9):865-71.

Downloads

Published

2017-01-20

How to Cite

Mahajan, M. M., Dudhgaonkar, S., & Deshmukh, S. N. (2017). Imprudent use of proton pump inhibitors in current practice. International Journal of Basic & Clinical Pharmacology, 4(1), 184–185. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/890

Issue

Section

Letter to the Editor